MACRO - MACRO
Guggenheim Securities LLC
PROK: Earnings In Line; Enrollment Continues for PROACT 1 Pivotal Trial of Rilparencel, With eGFR Slope Data Analysis Still Expected in 2Q 2027; Reiterate Buy Rating
公司
MACRO
日期
2026-03-18
分析师
Mr. Vamil K. Divan, MD
页数
5 页
需要登录
请登录后购买研报或生成音频内容。